Is There a Future for Anti-CD38 Antibody Therapy in Systemic Autoimmune Diseases?

CD38 is a type II glycoprotein highly expressed on plasmablasts, short-lived and long-lived plasma cells, but weakly expressed on other lymphoid cells, myeloid cells and non-hematopoietic cells. This expression pattern makes CD38 an interesting target for a targeted therapy aiming to deplete antibod...

Descripción completa

Detalles Bibliográficos
Autores principales: Benfaremo, Devis, Gabrielli, Armando
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Viewpoint
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7016693/
https://www.ncbi.nlm.nih.gov/pubmed/31892266
http://dx.doi.org/10.3390/cells9010077

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7016693/
https://www.ncbi.nlm.nih.gov/pubmed/31892266
http://dx.doi.org/10.3390/cells9010077

Ejemplares similares